On February 14, 2019, the PTAB issued final written decisions in two separate IPRs filed by Sanofi-Aventis, Genzyme Corp., and Regeneron Pharmaceuticals (collectively “Sanofi”) against U.S. Patent No. 8,679,487 (“the ʼ487 patent”) assigned to Immunex Corporation (“Immunex”). Claim 1 of the ʼ487 patent is the only independent claim, and it is directed to “an isolated
Latest Post
More Posts
Sandoz Files Declaratory Judgment of Non-Infringement For Filgrastim-Related Patent
The PTAB Denies Institution of Two IPRs Involving a Patent Directed to the Treatment of Hemophilia B
FDA Issues Guidance Documents on the “Deemed to be a License” Transition Provision of the BPCIA
FDA Proposes Amendment to the Definition of “Biological Product”
AbbVie Files Suit Against Sandoz Alleging Infringement of Two Humira®-Related Patents
Genentech Files Suit Alleging Eli Lilly’s Taltz® Product Infringes a Newly Issued Genentech Patent
Genentech Files Two New Lawsuits Against Celltrion Alleging Infringement of Patents Related to Rituxan® and Herceptin®
Lilly Announces Positive Results for Galcanezumab in Treating Episodic Cluster Headaches
Novartis and Amgen Announce FDA Approval of Aimovig™
Subscribe: Subscribe via RSS
Blogs
Firm/Org